FDG-PET/CT for oral focus assessment in head and neck cancer patients.
Head and neck cancer
Oral focus
Panoramic radiography
Periapical radiography
Positron emission tomography–computed tomography
Radiochemotherapy
Journal
Clinical oral investigations
ISSN: 1436-3771
Titre abrégé: Clin Oral Investig
Pays: Germany
ID NLM: 9707115
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
05
05
2021
accepted:
06
02
2022
pubmed:
8
3
2022
medline:
22
6
2022
entrez:
7
3
2022
Statut:
ppublish
Résumé
To compare oral and maxillo-mandibular inflammatory foci on standard oral radiographs (OPT, periapical radiograph) with available fluorine-18-labelled fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) data and to discuss whether additional metabolic information derived from FDG-PET/CT can support oral care specialists when performing oral focus examinations. Data from 23 patients with head and neck cancer who underwent FDG-PET/CT and panoramic and periapical radiography in close succession before first-line radiotherapy and/or chemotherapy were included in this exploratory retrospective study. Periapical lesions and marginal periodontal inflammation on FDG-PET/CT scans and standard oral radiographs were analysed and compared with regard to metabolic activity on FDG-PET/CT in comparison to recorded clinical symptoms and radiological scores. Additionally, inflammatory maxillo-mandibular pathologies were analysed using FDG-PET/CT. The maximum standardised uptake value (SUV FDG-PET/CT provided additional metabolic information that can help clinicians identify lesions with increased inflammatory activity. The incorporation of available oral FDG-PET/CT findings into the primary oral focus assessment may allow for more accurate oral focus treatment. FDG-PET/CT provides valuable metabolic information for oral care specialists. The detection of inflammatory oral processes using FDG-PET/CT facilitates treatment.
Identifiants
pubmed: 35254526
doi: 10.1007/s00784-022-04403-2
pii: 10.1007/s00784-022-04403-2
pmc: PMC9203386
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Pagination
4407-4418Informations de copyright
© 2022. The Author(s).
Références
Oral Oncol. 2017 Jan;64:44-51
pubmed: 28024723
Swiss Med Wkly. 2015 Feb 21;145:w14116
pubmed: 25701645
N Engl J Med. 2016 Apr 14;374(15):1444-54
pubmed: 27007578
Oral Dis. 2021 Jan;27(1):7-13
pubmed: 32166855
Am J Nucl Med Mol Imaging. 2019 Dec 15;9(6):255-273
pubmed: 31976156
Support Care Cancer. 2018 Apr;26(4):1133-1142
pubmed: 29090383
Clin Oral Investig. 2016 May;20(4):721-6
pubmed: 26250794
Clin Oncol (R Coll Radiol). 2012 Sep;24(7):474-87
pubmed: 22770590
Clin Otolaryngol. 2018 Dec;43(6):1594-1599
pubmed: 29974995
Ann Hematol. 2017 Jul;96(7):1135-1145
pubmed: 28194493
Br J Cancer. 2016 Apr 26;114(9):972-8
pubmed: 27002936
J Natl Compr Canc Netw. 2020 Jul;18(7):873-898
pubmed: 32634781
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):396-402
pubmed: 17321069
Head Neck. 2019 Feb;41(2):503-510
pubmed: 30561113
Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):e62-9
pubmed: 23021921
Cancer Med. 2017 Dec;6(12):2918-2931
pubmed: 29071801
Br J Oral Maxillofac Surg. 2000 Oct;38(5):519-24
pubmed: 11010786
Br J Radiol. 2019 Apr;92(1096):20180792
pubmed: 30673302
Strahlenther Onkol. 2003 Apr;179(4):275-8
pubmed: 12728932
Oral Oncol. 2010 Jun;46(6):475-9
pubmed: 20400359
Int J Oral Maxillofac Surg. 2011 Mar;40(3):229-43
pubmed: 21115324
Schweiz Monatsschr Zahnmed. 2011;121(3):216-29
pubmed: 21534021
J Oral Maxillofac Surg. 2017 Dec;75(12):2562-2572
pubmed: 28618252
Endod Dent Traumatol. 1986 Feb;2(1):20-34
pubmed: 3457698
Clin Oral Investig. 2007 Jun;11(2):171-4
pubmed: 17431693
Ann Oncol. 2020 Nov;31(11):1462-1475
pubmed: 33239190
Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Aug;122(2):242-9
pubmed: 27422423
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593